[Federal Register Volume 85, Number 108 (Thursday, June 4, 2020)]
[Notices]
[Page 34466]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-12082]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-654]


Importer of Controlled Substances Application: Bellwyck Clinical 
Services

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before July 6, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before July 6, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on May 19, 2020, Bellwyck Clinical Services, 8946 Global 
Way, West Chester, Ohio 45069, applied to be registered as an importer 
of the following basic class(es) of controlled substances:

------------------------------------------------------------------------
                                           Drug
         Controlled substances             code          Schedule
------------------------------------------------------------------------
Amphetamine............................     1100  II
Methylphenidate........................     1724  II
Oxycodone..............................     9143  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances in 
dosage form to conduct clinical trials. Approval of permit applications 
will occur only when the registrant's activity is consistent with what 
is authorized under 21 U.S.C. 952(a) (2). Authorization will not extend 
to the import of Food and Drug Administration (FDA)-approved or non-
approved finished dosage forms for commercial sale.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-12082 Filed 6-3-20; 8:45 am]
 BILLING CODE 4410-09-P